HNRNPA2B1 and breast cancer: In addition to METTL3, HNRNPA2B1 overexpression also enhanced the resistance of MCF-7 to tamoxifen and fulvestrant, suggesting that HNRNPA2B1 has a role in possible endocrine resistance [150] and that inhibition of HNRNPA2B1 might be a completely new road to treating endocrine resistant BC [151].